TheEdgeResearch
Home / Stocks / BRNHF

Broncus Holding Corporation (BRNHF)

OTC Healthcare Medical - Devices
$0.08 ▲ +0.00%
Market Cap
$42.1M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.19
52-Wk Range
0.08-0.08
CEO
Hong Xu
Country
CN
Currency
USD

Broncus Holding Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Hangzhou, CN. The stock last traded at $0.08, up 0.00% on the session, giving a market capitalisation of $42.1M. On trailing twelve-month figures it carries a trailing P/E of -2.10, a net margin of -10273.0%. Its beta of 1.19 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-2.10
Price / Sales
234.90
Price / Book
0.25
EV / EBITDA
-0.40
Gross margin
-1585.1%
Operating margin
-14017.8%
Net margin
-10273.0%
Return on equity
Debt / equity
0.00
Current ratio
22.70
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
191
IPO date
2022-09-19
Headquarters
Hangzhou, CN
About Broncus Holding Corporation

Broncus Holding Corporation is a medical technology enterprise dedicated to advancing interventional pulmonology through the development of specialized products. Its operational reach extends across key markets including Mainland China, the European Union, the United States, and other international regions. The company's product portfolio is broadly categorized into navigation and treatment solutions. Navigation offerings include: LungPoint Virtual Bronchoscopic Navigation: A sophisticated, computer-assisted software system that utilizes imaging for virtual bronchoscopic guidance. LungPoint Plus: This system provides real-time navigational assistance within the airways, crucial for lung biopsies and various other pulmonological procedures. LungPro: A virtual bronchoscopic navigation tool that facilitates three-dimensional, real-time guided transbronchial needle aspiration and features proprietary parenchymal navigation capabilities. Its comprehensive suite of treatment products comprises: InterVapor: A targeted bronchoscopic thermal vapor ablation method designed to treat diseased, hyper-inflated lung segments. RF Generator + RF Ablation Catheter: A radiofrequency ablation system specifically engineered for use with a disposable lung radiofrequency ablation catheter, targeting lung cancer. H-Marker: A specialized marker for pulmonary surgical applications. Furthermore, Broncus provides essential procedural accessories and tools such as: BioStarNeedle: A single-use, ultrasound-guided aspiration needle for efficiently collecting tissue samples. FleXNeedle: A versatile biopsy needle adaptable for multiple purposes. Archimedes Sheath: A sterile, single-use flexible tube that establishes a working channel during bronchoscopic interventions. Archimedes Dilation Balloon: A sterile, single-use flexible tube equipped with a balloon at its tip, inserted via a bronchoscope or sheath to dilate targeted lung tissue within the bronchial tree. Steerable Sheath: Featuring a steerable adjustment handle and a working channel for enhanced maneuverability. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.

Comparable companies

Broncus Holding Corporation is most often compared with the following Healthcare names:

ADOCYAMCYAMEUFCKMTFCMXCCOLRFEKDHFNNGRFRECEFRSHUF
More research on BRNHF
BRNHF technical analysis BRNHF TheEdge Score Compare against peers
Open full interactive analysis & DCF →